Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166624 | 0.86 | PTGS2 (0.63) | PTGS2PTGS1LRRK2SYKVCP | |
| SCHEMBL14002222 | 0.78 | PTGS2 (0.36) | PTGS2CARM1 | |
| SCHEMBL3161223 | 0.75 | PTGS2 (0.65) | PTGS2PTGS1SYK | |
| SCHEMBL5826798 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3171349 | 0.74 | PTGS2 (0.49) | PTGS2PTGS1LRRK2SYKVCP | |
| SCHEMBL3118181 | 0.72 | PTGS2 (0.65) | PTGS2PTGS1SYK | |
| SCHEMBL3161588 | 0.70 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL3161824 | 0.70 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL3168024 | 0.70 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL3153521 | 0.70 | PTGS2 (0.69) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546107-B1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885CARM1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.